Abstract
Objective
The purpose of this paper is to consolidate existing evidence and identify knowledge and research gaps on the bone health effects of progestin-only oral contraception, injectables, hormonal intrauterine devices, and implants. implementation.
Data sources
We searched PubMed, CINAHL, Web of Science, and The Cochrane Library for conference abstracts, original research articles, systematic reviews, and meta-analyses published between 05 May 2012 and 31 August 2023.
Study eligibility criteria
We limited results to any study design published as a conference abstract, original research study, meta-analysis, or systematic review in English-language peer-reviewed journals.
Study appraisal and synthesis methods
Two independent reviewers screened item titles. One reviewer read all abstracts and full papers, and a second reviewer confirmed alignment with a 5% sample of each. One reviewer extracted relevant information into Excel with a 5% sample review by another research team member. We reviewed the references for all included items and screened potentially relevant items in the same manner as described above. Subject matter experts contributed additional items. We assessed items using the Mixed Methods Appraisal tool.
Results
The search strategy yielded 32 items, most of which explored the use of intra-muscular depot medroxyprogesterone acetate 150mg. We found a clear association between any use of depot medroxyprogesterone acetate and bone mineral density loss. This negative effect seems to be more common among younger women and women on antiretrovirals. There is, however, evidence to suggest that bone loss can be restored after depot medroxyprogesterone acetate discontinuation. Hormonal intrauterine device and implant users do not seem to experience bone mineral density loss.
Conclusions
While there is a clear association between bone mineral density loss and depot medroxyprogesterone acetate injectable use, treatment during contraceptive use and bone health restoration following discontinuation are not adequately researched. In this review, we provide evidence that bone health can be partially or completely restored after depot medroxyprogesterone acetate discontinuation, identify opportunities to learn more about depot medroxyprogesterone acetate injectables and bone health during and after use, and find gaps in knowledge on potential associations between bone health and other progestin-only contraceptives.
Keywords: Bone health, Bone mineral density, Contraception, Contraceptive, Depo Provera
AJOG Global Reports at a Glance.
Why was this study conducted?
This study aimed to consolidate evidence on the effects of progestin-only contraceptives (oral, injectable, IUDs, and implants) on bone health to guide research, clinical practice, and contraceptive policy.
Key findings
Depot medroxyprogesterone acetate (DMPA) injectables are linked to bone mineral density (BMD) loss, particularly in adolescents. Hormonal IUDs and implants show no significant negative impact on BMD. Bone health can partially or fully recover after discontinuation of DMPA, but treatments for BMD loss during use remain under-explored.
What does this study add to what is already known?
The study provides a comparison of progestin-only contraceptives and identifies significant gaps, such as the need for more research on oral contraceptives and the clinical relevance of BMD changes. The findings highlight potential for recovery post-DMPA discontinuation and emphasizes the importance of further exploration into treatments during contraceptive use.
Introduction
The first progestin-only contraceptive method, the "mini-pill" was approved for use in 1973.1 Progestin-only contraceptive methods became popular in the early 2000s as an alternative to estrogen dominant methods that had blood clotting side effects, and after the discovery that progestin prevents ovulation when administered at a high dose.2 The side effects most commonly associated with progestin-only methods are unscheduled bleeding and changes in menstruation, delayed return to fertility, acne, hirsutism, follicular ovarian cysts, and bone mineral density (BMD) changes.3
Among the progestin-only oral contraceptives, injectables, hormonal intrauterine devices (IUDs), and implants approved in the United States by the Food and Drug Administration,4, 5, 6, 7, 8, 9, 10, 11, 12 only the dossiers for Slynd (a drosperinone oral contraceptive) and depot medroxyprogesterone acetate (DMPA) injectables mention bone health. The Food and Drug Administration dossier for Slynd does not include clinical trial results related to BMD changes, but notes that it is unknown whether decreased estradiol serum levels caused by the product are related to clinically relevant loss of bone mineral density.9 The Depo Provera, or DMPA 150mg intramuscular (IM), label carries a short “Black Box” warning, stating only that Depo Provera use is considered “among the risk factors for development of osteoporosis” and that BMD loss is greatest in the initial years of contraceptive use and then declines.13 However, the Food and Drug Administration’s “Highlights of Prescribing Information” carries a clear warning for BMD loss, which was added to the prescription label in October 2010.14 In Europe, the Sayana Press, or DMPA 104mg subcutaneous (SC), dossier includes a special warning related to BMD, particularly due to unknown BMD loss among adolescent girls.15 The dossier specifically discusses how the contraceptive reduces estrogen levels and leads to greater BMD loss with increased use, and notes that BMD increases after discontinuation as estrogen production increases.
Estrogens and progesterone have a vital role in skeletal growth, development, and remodeling.16 These sex hormones act directly on the cells responsible for bone deposition and resorption. Estrogens modulate bone resorption by acting on osteoclastic and osteoblastic cells. Although progesterone itself has no direct bone effect, it supports estrogens in obtaining peak bone mass and maintaining an optimal bone metabolism.17 DMPA strongly suppresses the production of endogenous estrogens by the ovaries resulting in a prolonged hypoestrogenism (circulating concentrations of estrogen of 20-30pg/mL or below) that in addition to the partial glucocorticoid effect on bone is the primary mechanism by which DMPA exerts a detrimental effect on bone health.
Objectives
The purpose of this paper is to consolidate recent evidence and identify knowledge and research gaps on the bone health effects of progestin-only oral contraception, injectables, hormonal IUDs, and implants. In this investigation we use a broad approach to include multiple progestin active pharmaceutical ingredients and routes of delivery, allowing for comparison within and across these domains. Results can inform related research priorities, bone health warnings on contraceptive labels and testing requirements during clinical trials for new products, as well as global contraceptive program implementation. This study is part of a broader rapid review that explored 5 side effects and adverse outcomes (changes in menstrual bleeding patterns, changes in body weight, changes in bone health, return to fertility following discontinuation, and risk of ectopic pregnancy during contraceptive use and following discontinuation) associated with progestin-only contraceptives (oral contraceptives, emergency oral contraceptives, injectables, hormonal IUDs, and implants). Ultimately, we hope that this review provides critical information to healthcare practitioners and program implementers to ensure that individuals are able exercise their reproductive right to safely access the contraceptive method that they desire.
Methods
We conducted a rapid review to produce results in a timely manner. We made this decision to reduce implementation time and therefore reduced the number of databases searched to 4, used a single reviewer with a second "verifier" in most steps, and limited review of the grey literature. Full details of the methodology employed in this rapid literature review are available in the registered protocol on PROSPERO (#CRD42022337263c).18
Eligibility criteria, information sources, and search strategy
We conducted 3 searches for the period May 2012 through August 2023 on PubMed, CINAHL, Web of Science, and The Cochrane Library for the full set of keywords for all progestin-only contraceptive methods and side effects/adverse outcomes of interest (see Appendix A for the full set of search terms). We originally searched for ten years of research (May 2012 - May 2022) but updated our search to include articles published through August 2023 before finalizing this manuscript.
We limited results to conference abstracts, original research studies, meta-analyses, and systematic reviews in peer-reviewed journals. This includes items that are cited in other meta-analyses and systematic reviews. We did not independently screen each individual citation in the included meta-analyses and systematic reviews for their ability to meet inclusion criteria in this review and included them if the meta-analysis or systematic review met inclusion criteria. We included only items published in the English language.
Study selection
Two independent reviewers screened item titles. One reviewer read all abstracts and full papers, and a second reviewer confirmed alignment with a 5% sample of each. We reviewed the references for all included items and screened potentially relevant items in the same manner as described above. Subject matter experts contributed additional items.
Data extraction
One reviewer extracted relevant information into Excel with a 5% sample review by another research team member. We considered the following bone health-related outcomes in this review: BMD (total, total hip, lumbar spine, femoral neck, calcaneus), BMD Z-score (total, total hip, lumbar spine, femoral neck, calcaneus), bone metabolism (total, total hip, lumbar spine, femoral neck, calcaneus), broadband ultrasound attenuation, and fracture prevalence. We assessed both longitudinal studies that compared results for individuals at different time points and studies that compared progestin-only contraceptive method users, other hormonal contraceptive method users, non-hormonal contraceptive users, and non-users of contraception.
Assessment of risk of bias
We completed quality screening using the Mixed Methods Appraisal Tool 2018.19 We reviewed original research articles and abstracts, but not systematic reviews and meta-analyses. We selected this tool because it appraises 5 different study types: qualitative, mixed methods, quantitative descriptive, quantitative non-randomized, and quantitative randomized controlled. Each of these study types appeared in our broad rapid review, though not all study types may be represented in reviews for specific side effects. Comparisons in quality across study types is not possible because the Mixed Methods Appraisal Tool 2018 appraises each study type separately. There are 7 criteria in the Mixed Methods Appraisal Tool 2018 which can receive a “yes," “no," or “unsure." We weighed each criterion equally and considered research items to be high quality if they received a “yes” for each response, medium quality if they received a “yes” for 5 or 6 responses and assigned all other items low quality.
Data synthesis
We present the results by contraceptive method category: oral contraception, injectables, hormonal IUDs, and implants. Though emergency contraception was included in our broad rapid review, we do not include it here because we do not expect bone health changes from such a short levonorgestrel exposure.
In Table 1, Table 2, Table 3, Table 4, there is a column labeled “Significance and direction of effect." In this column, we use “+," “-," “∼," and “Not significant” to denote the significance of findings and direction of effect. Due to the various ways of reporting on bone health and confusion that could be introduced by simply using “-” for a negative association and “+” for a positive association between variables, we use “-” to denote whether use of the contraceptive method had a statistically significant deleterious effect on bone health relative to self at baseline or compared to another group and “+” to mark where the contraceptive method had a statistically significant positive effect on bone health. The "∼" marks mixed findings within systematic reviews. For example, if the item's summary is “Depo Provera lowers or does not affect BMD," we use a mix of symbols, and in that instance, “-/∼” to show lack of clarity. A “#” refers to items with no comparison to self at baseline and a “^” refers to items with no comparison to other groups. The next column in these tables is “Magnitude of effect;” there are only values in this column if specific values were reported in the item. Lettered superscripts link to footnotes that describe the comparison group in greater detail.
Table 1.
Items exploring bone health side effects among progestin-only oral contraceptive users or past users that are included in this rapid review
| Product | Author(s) | Year | Study design | Geography | Study aim | Sample | Duration | Significance and direction of effect | Magnitude of effect | Quality |
|---|---|---|---|---|---|---|---|---|---|---|
| NET progestin-only oral contraception | Rocca, ML, et al.16 | 2021 | Systematic review | Not reported | To better understand how short- and long-term steroid contraceptives increase overall fracture risk. | Not applicable | Not applicable | Not significant (#) | Does not affect BMD | Not applicable |
| Dienogest progestin-only oral contraception | Rocca, ML, et al.16 | 2021 | Systematic review | Not reported | To better understand how short- and long-term steroid contraceptives increase overall fracture risk. | Not applicable | Not applicable |
-/∼ (#a) |
Does not affect or lowers BMD | Not applicable |
| Progestin-only oral contraception (unspecified) | Raine-Bennett, T, et al.20 | 2019 | Quantitative non-randomized | United States | To assess fracture risk among women with DMPA, oral contraceptive, and IUD use. | 12,244 DMPA, 161,005 combined pill, 14,280 progestin-only pills, and 30,311 hormonal IUD participants; Participants were women from Kaiser Permanente Northern California who were age 12–45 years and initiated DMPA, combined or progestin-only oral contraceptives, or a copper or hormonal IUD. | Cross-sectional |
+ (#b) |
0.88 hazard ratio for fracture | High |
#Not evaluated for statistical significance against baseline.
^Not evaluated for statistical significance compared to another group.
aValue is statistically significantly lower at p < 0.05 in some studies compared to other groups.
bValue is statistically significantly lower at p < 0.05 compared to non-oral contraceptive users.
Erhardt-Ohren. Bone mineral density changes during use of progestin-only contraceptives. Am J Obstet Gynecol 2025.
Table 2.
Items exploring bone health side effects among progestin-only injectable users or past users that are included in this rapid review
| Product | Author(s) | Year | Study design | Geography | Study aim | Sample | Duration | Significance and direction of effect | Magnitude of effect | Quality |
|---|---|---|---|---|---|---|---|---|---|---|
| DMPA-IM 75mg | Lange, HLH, et al.27 | 2017 | Quantitative randomized controlled trial | United States | To assess the association between DMPA exposure and BMD loss and weight change in adolescents. | 34 participants; Healthy, postmenarchal, female participants aged 12-21 years who self-selected to initiate DMPA and were willing to additionally use a barrier contraceptive method. Participants were recruited from Nationwide Children's Hospital, local colleges, and universities using study flyers and institutional e-mails. | 48 weeks | Not significant | -0.1% total hip BMD -0.6% L1-L4 spine BMD -2.7% femoral neck BMD |
Medium |
| DMPA-IM 104mg | Lange, HLH, et al.27 | 2017 | Quantitative randomized controlled trial | United States | To assess the association between DMPA exposure and BMD loss and weight change in adolescents. | 34 participants; Healthy, postmenarchal, female participants aged 12-21 years who self-selected to initiate DMPA and were willing to additionally use a barrier contraceptive method. Participants were recruited from Nationwide Children's Hospital, local colleges, and universities using study flyers and institutional e-mails. | 48 weeks | - (^a) |
-1.6% total hip BMD -3.1% L1-L4 spine BMD -2.6% femoral neck BMD |
Medium |
| DMPA-SC 104mg | Segall-Gutierrez, P, et al.23 | 2013 | Quantitative non-randomized | United States | To examine changes in lumbar spine-BMD among normal weight, Class 1–2 obese, and Class 3 obese women using DMPA. | 15 participants; Study subjects were recruited from all outpatient gynecology clinics at the Los Angeles County: University of Southern California Medical Center. | 18 weeks |
- (^b) |
Decrease in lumbar-spine BMD | Medium |
| DMPA-IM 150mg | Rocca, ML, et al.16 | 2021 | Systematic review | Not reported | To better understand how short- and long-term steroid contraceptives increase overall fracture risk. | Not applicable | Not applicable |
- (c) |
BMD lower among DMPA users | Not applicable |
| DMPA-IM 150mg | Mgodi, NM, et al.37 | 2015 | Quantitative descriptive | Zimbabwe, Uganda | To determine the factors associated with BMD in healthy premenopausal women in Uganda and Zimbabwe. | 518 participants; Eligible participants were HIV-negative, sexually active, had normal urinalysis, and no laboratory evidence of hepatic, renal, or hematological disease. | Cross-sectional |
- (#d) |
Association between DMPA use and lower BMD at lumbar-spine and total hip | Medium |
| DMPA-IM 150mg | Begum, RA, et al.31 | 2015 | Quantitative descriptive | Bangladesh | To estimate reference values of BMD, along with their correlates, for women living in urban and suburban areas of Bangladesh. | 500 participants; Participants were between 16 and 65 years. | Cross-sectional | Not significant (#) |
No association between DMPA use and lower BMD at lumbar-spine and femoral neck | Medium |
| DMPA-IM 150mg | Mahran, DG, et al.26 | 2012 | Quantitative descriptive | Egypt | To estimate the prevalence of low BMD among rural women of reproductive age in Upper Egypt and to evaluate the association of selected anthropometric, reproductive, lifestyle and socioeconomic class factors on BMD. | 362 participants; Participants were contraceptive users registered in the family planning clinics in the Tema District and 4 villages related to it in Sohag Governorate, Upper Egypt. | Cross-sectional |
- (#e) |
Association between DMPA use and lower BMD at calcaneus | Medium |
| DMPA-IM 150mg | Modesto, W, et al.40 | 2015 | Quantitative non-randomized | Brazil | To compare the difference in osteoporosis and low bone mass between DMPA and copper IUD users. | 47 DMPA user and 41 copper IUD user participants. Participants were DMPA users and non-users. DMPA users were women 27-57 years old, who had been using DMPA uninterruptedly for at least 10 years or 40 doses, who started using the method prior to 40 years of age, and who had at least 2 consecutive (90 days apart) follicle-stimulating hormone measurements <40 mIU/mL. The non-user group consisted of current users of the copper IUD who had never used DMPA. Non-users had had regular menstrual cycles for the year preceding the study and had not used any other hormonal contraceptive method for more than 6 months during their reproductive lives or in the 6 months preceding the study. | Cross-sectional |
- (#f) |
Bone mass at lumbar-spine and femoral neck lower among DMPA users | Medium |
| DMPA-IM 150mg | Babatunde, OO, et al.25 | 2014 | Quantitative non-randomized | United Kingdom | To examine the relationship between physical activity and bone health of DMPA users, and to investigate whether quantitative ultrasound measurements of DMPA users and non-users differed according to physical activity. | 48 DMPA users (of at least 6 months or more) and 48 match participants. | Cross-sectional |
- (#g) |
-6.54 dB/MHz broadband ultrasound attenuation | Medium |
| DMPA-IM 150mg | Roden, RC, et al.24 | 2020 | Quantitative non-randomized | United States | To explore whether use of DMPA in adolescent and young adult females with cerebral palsy is associated with lower BMD. | 103 participants; Participants were under 30 years old. | Cross-sectional | Not significant (#) |
-1.31 total body BMD Z-score | Medium |
| DMPA-IM 150mg | Lange, HLH, et al.27 | 2017 | Quantitative randomized controlled trial | United States | To assess the association between DMPA exposure and BMD loss and weight change in adolescents. | 34 participants; Healthy, postmenarchal, female participants aged 12-21 years who self-selected to initiate DMPA and were willing to additionally use a barrier contraceptive method. Participants were recruited from Nationwide Children's Hospital, local colleges, and universities using study flyers and institutional e-mails. | 48 weeks |
- (^h) |
-3.0% total hip BMD -4.0% L1-L4 spine BMD -4.0% femoral neck BMD |
Medium |
| DMPA-IM 150mg | Quintino-Moro, A, et al.32 | 2019 | Quantitative non-randomized | Brazil | To evaluate calcium metabolism and BMD in new users of DMPA in the first year of use. | 27 DMPA user and 24 copper IUD user participants; Participants were 18–40 years old, with a body mass index <30, and a 75-g oral glucose tolerance test with fasting glucose levels <100 mg/ dL and 2-hour glucose levels <140 mg/dL, and no history of previous DMPA use. | 1 year |
- (#i) |
-3.6% lumbar-spine BMD -2.1% femoral neck BMD |
Medium |
| DMPA-IM 150mg | Modesto, W, et al.36 | 2014 | Quantitative non-randomized | Brazil | To compare variations in bone mineral density and body composition in DMPA users and non-users after providing counselling on healthy lifestyle habits. | 29 DMPA and 25 other contraceptive users; Participants were 18- 40 years old and had a body mass index <30 kg/m2. | 1 year |
- (^j) |
Association between DMPA use and BMD loss at lumbar-spine L1 and L4 | Low |
| DMPA-IM 150mg | Kyvernitakis, I, et al.41 | 2017 | Quantitative non-randomized | United Kingdom | To assess the association between use of DMPA or combined oral contraceptives and the incident risk of fracture. | 4,189 case and 4,189 control participants; First-time fracture diagnosis (including vertebral and non- vertebral fractures). | At least 1 year | Not significant (#) |
11% of fracture cases used DMPA | High |
| DMPA-IM 150mg | Zhang, MH, et al.34 | 2013 | Quantitative non-randomized | China | To compare BMD between users of DMPA-IM and nonhormonal subjects. | 102 DMPA and 97 nonhormonal contraceptive user participants; Participants were 16-18 years old. | 1, 2 years |
- (k) |
-0.99%, 1.47% lumbar-spine BMD -1.88%, -2.32% femoral neck BMD |
High |
| DMPA-IM 150mg | Nieves, JW, et al.33 | 2016 | Quantitative non-randomized | United States | To simultaneously evaluate factors influencing 4-year BMD change and changes in BMD in college aged women. | 91 participants; Participants were all cadets from 1 class at USMA in West Point. | 4 years |
- (#l) |
-0.65% lumbar spine BMD -1.00% total hip BMD -1.0% calcaneus BMD |
Medium |
| NET-EN 200mg | Beksinska, ME, et al.29 | 2018 | Quantitative non-randomized | South Africa | To investigate BMD in pre and perimenopausal users of DMPA, NET-EN, combined oral contraceptive, and non-users of contraception in a 4–5-year follow-up study and review as- sociations with body mass index and menopausal status. | 127 DMPA, 102 NET-EN, 106 combined oral contraceptives, 161 control participants; Participants were women 40-49 years old using DMPA, NET-EN, or combined oral contraceptives, and non-users of hormonal contraception. | Cross-sectional, 2.5 years | Not significant (#) |
0.514, 0.501 radius BMD g/cm2 average | Medium |
| DMPA (unspecified) | Nappi, C, et al.22 | 2012 | Systematic review | Not reported | To explore the effect of contraceptives on fracture risk. | Not applicable | Not applicable |
- (^m) |
BMD lower among DMPA users | Not applicable |
| DMPA (unspecified) | Golden, NH.21 | 2020 | Systematic review | Not reported | To summarize normal bone acquisition during adolescence, discusses methods of assessing bone health in this age group, and review the effects of different contraceptive options on bone health, both in adults and in adolescents. | Not applicable | Not applicable | Not applicable (#^) |
Association between DMPA use and BMD loss | Not applicable |
| DMPA (unspecified) | Matovu, FK, et al.44 | 2017 | Not reported | Uganda | To determine whether certain dietary patterns are associated with low BMD of the lumbar spine among DMPA users and non-hormonal contraceptive users in a group of African women. | 100 DMPA and 51 non-hormonal method user participants. | Cross-sectional | Not applicable (#^) |
52 (52%) with low BMD at lumbar-spine | Not applicable |
| DMPA (unspecified) | Coombs, CV, et al.38 | 2020 | Quantitative descriptive | United Kingdom | To investigate bone density and biochemical markers of bone metabolism in women taking hormonal contraceptives on entry to basic military training. | 45 participants; Participants were female standard entry British Army recruits. | Cross-sectional | Not significant (#) |
BMD similar to others at lumbar-spine, left femoral neck, Ward’s Triangle, left total hip, whole-body, pelvis, or left leg | High |
| DMPA (unspecified) | Beksinska, ME, et al.29 | 2018 | Quantitative non-randomized | South Africa | To investigate BMD in pre and perimenopausal users of DMPA, NET-EN, combined oral contraceptive, and non-users of contraception in a 4–5-year follow-up study and review as- sociations with body mass index and menopausal status. | 127 DMPA, 102 NET-EN, 106 combined oral contraceptives, 161 control participants; Participants were women 40-49 years old using DMPA, NET-EN, or combined oral contraceptives, and non-users of hormonal contraception. | Cross-sectional, 2.5 years | Not significant (#) |
0.514, 0.511 radius BMD g/cm2 average | Medium |
| DMPA (unspecified) | Raine-Bennett, T, et al.20 | 2019 | Quantitative non-randomized | United States | To assess fracture risk among women with DMPA, oral contraceptive, and hormonal IUD use. | 12,244 DMPA, 161,005 combined pill, 14,280 progestin-only pills, and 30,311 hormonal IUD participants; Participants were women from Kaiser Permanente Northern California who were age 12–45 years and initiated DMPA, combined or progestin-only oral contraceptives, or a copper or hormonal IUD. | Cross-sectional |
- (#n) |
1.18 hazard ratio for fracture | High |
| DMPA (unspecified) | Lanza, LL, et al.42 | 2013 | Quantitative non-randomized | United Kingdom | To estimate the extent to which DMPA might increase fracture risk, we undertook a retrospective cohort study of fractures in DMPA users and users of non-DMPA contraceptives, using the General Practice Research Database. | 312,395 participants; Participants had known year of birth; and at least one prescription contraceptive record, including DMPA, oral contraceptives, IUDs, cervical cap, or diaphragm, were less than 50 years old, and before any record of bilateral oophorectomy. | Cross-sectional |
- (o) |
9.1 fractures/1,000 person-years | High |
#Not evaluated for statistical significance against baseline.
^Not evaluated for statistical significance compared to another group.
aValue for L1-L4 spine is statistically significantly lower at P<.05 compared to self at baseline; values for total hip and femoral neck are not significantly different.
bValue is statistically significantly lower at P<.05 compared to self at baseline.
cFive studies reported adverse effects of DMPA-IM 150mg on bone BMD; 5 studies found significant reductions in BMD that increased over time, with some studies continuing up to 13 years.
dValue is statistically significantly lower at P<.05 compared to other contraceptive users and non-users.
eValue is statistically significantly lower at P<.05 compared to other non-hormonal contraceptive method users, combined oral contraceptive users, and etonogestrel implant 68mg users.
fValue is statistically significantly lower at P<.05 compared to non-hormonal copper IUD users. DMPA-IM 150mg users were also statistically significantly more likely to have osteoporosis, mean BMD at lower spine and femoral neck.
gValue is statistically significantly lower at P<.05 compared to non-users.
hValues for L1-L4 spine, total hip, and femoral neck are statistically significantly lower at P<.05 compared to self at baseline.
iValue for loss of lumbar-spine BMD is statistically significantly lower at P<.05 compared to non-hormonal copper IUD users.
jValue is statistically significantly lower at P<.05 compared to self at baseline.
kValue is statistically significantly lower at P<.05 compared to non-users at 2 years only.
lValue is statistically significantly lower at P<.05 compared to non-users.
mResults from 6 studies included in 1 systematic review, including cross-sectional and longitudinal studies.
nHazard of fracture about DMPA users is statistically significantly higher at P<.05 compared to other contraceptive method users and non-users.
oHazard of fracture about DMPA users is statistically significantly higher at P<.05 compared to non-users of contraceptive methods.
Erhardt-Ohren. Bone mineral density changes during use of progestin-only contraceptives. Am J Obstet Gynecol 2025.
Table 3.
Items exploring bone health side effects among progestin-only hormonal IUD users or past users that are included in this rapid review
| Product | Author(s) | Year | Study design | Geography | Study aim | Sample | Duration | Significance and direction of effect | Magnitude of effect | Quality |
|---|---|---|---|---|---|---|---|---|---|---|
| Hormonal IUD 13.5mg | Nelson, A, et al.46 | 2013 | Quantitative randomized controlled trial | Argentina, Canada, Chile, Finland, France, Hungary, Mexico, The Netherlands, Norway, Sweden, and the United States | To evaluate the efficacy and safety of 2 hormonal IUDs. | 1,432 13.5mg hormonal IUD and 1,452 19.5mg hormonal IUD participants; Participants were healthy nulliparous and parous women 18–35 years old that had regular menstrual cycles (21–35 days) and requested contraception. | 3 years | Not significant (^) |
Lumbar spine and lower hip BMD similar | High |
| Hormonal IUD 19.5mg | Nelson, A, et al.46 | 2013 | Quantitative randomized controlled trial | Argentina, Canada, Chile, Finland, France, Hungary, Mexico, The Netherlands, Norway, Sweden, and the United States | To evaluate the efficacy and safety of 2 hormonal IUDs. | 1,432 13.5mg hormonal IUD and 1,452 19.5mg hormonal IUD participants; Participants were healthy nulliparous and parous women 18–35 years old that had regular menstrual cycles (21–35 days) and requested contraception. | 3 years | Not significant (^) |
Lumbar spine and lower hip BMD similar | High |
| Hormonal IUD 52mg | Yang, KY, et al.47, Jung, MH & Ji, YI.49 | 2012 | Quantitative non-randomized | South Korea | To evaluate changes in BMD in patients using a hormonal IUD or a copper IUD after 2 years. | 38 hormonal IUD and 26 copper IUD participants; Participants were all patients who underwent hormonal IUD or copper IUD insertion, 40-45 years old at the time of insertion, had undergone a BMD examination of the femur and lumbar spine before the loop insertion, and had also received a follow-up BMD examination 2 years later. | 2 years | Not significant (^) |
BMD similar | Medium |
| Hormonal IUD (unspecified) | Rocca, ML, et al.16 | 2021 | Systematic review | Not reported | To better understand how short- and long-term steroid contraceptives increase overall fracture risk. | Not applicable | Not applicable |
+/∼ (#a) |
BMD similar or higher | Not applicable |
| Hormonal IUD (unspecified) | Golden, NH.21 | 2020 | Systematic review | Not reported | To summarize normal bone acquisition during adolescence, discusses methods of assessing bone health in this age group, and review the effects of different contraceptive options on bone health, both in adults and in adolescents. | Not applicable | Not applicable | Not applicable (#^) |
No association between hormonal IUD use and BMD loss | Not applicable |
| Hormonal IUD (unspecified) | Miller DL, et al.48 | 2013 | Conference abstract | Not reported | To determine if use of the hormonal IUD affects BMD. | 76 participants; Participants were 30-50 years old and had a current hormonal IUD inserted for 4-6 years, and matched (age, body mass index, smoking, and ethnicity) controls who had not been exposed to exogenous hormones or pregnancy for the previous 5 years. | Cross-sectional |
- (#b) |
Lower hip BMD z-score | Not applicable |
| Hormonal IUD (unspecified) | Raine-Bennett, T, et al.20 | 2019 | Quantitative non-randomized | United States | To assess fracture risk among women with DMPA, oral contraceptive, and hormonal IUD use. | 12,244 DMPA, 161,005 combined pill, 14,280 progestin-only pills, and 30,311 hormonal IUD participants; Participants were women from Kaiser Permanente Northern California who were 12–45 years old. | Cross-sectional | Not applicable (#^) |
1.04 hazard ratio for fracture | High |
#Not evaluated for statistical significance against baseline.
^Not evaluated for statistical significance compared to another group.
aIn 3 of 4 studies, hormonal IUD users had statistically significantly higher BMD than others at P<.05.
bValue is statistically significantly lower at P<.05 compared to matched controls.
Erhardt-Ohren. Bone mineral density changes during use of progestin-only contraceptives. Am J Obstet Gynecol 2025.
Table 4.
Items exploring bone health side effects among progestin-only implant users or past users that are included in this rapid review
| Product | Author(s) | Year | Study design | Geography | Study aim | Sample | Duration | Significance and direction of effect | Magnitude of effect | Quality |
|---|---|---|---|---|---|---|---|---|---|---|
| Etonogestrel implant 68mg | Rocca, ML, et al.16 | 2021 | Systematic review | Not reported | To better understand how short- and long-term steroid contraceptives increase overall fracture risk. | Not applicable | Not applicable | Not significant (#) |
Similar BMD | Not applicable |
|
Etonogestrel implant 68mg |
Modesto, W, et al.50 | 2015 | Quantitative non-randomized | Brazil | To evaluate body composition and BMD in etonogestrel implant users as compared to copper IUD users. | 38 etonogestrel implant and 37 copper IUD users; Participants were between 18-46 years old. | 1 year | Not significant (#) |
-0.010 g/cm2 lumbar spine BMD -0.007 g/cm2 femoral neck BMD |
Medium |
| Levonorgestrel implant 150mg | Mgodi, NM, et al.37 | 2015 | Quantitative descriptive | Zimbabwe, Uganda | To determine the factors associated with BMD in healthy premenopausal women in Uganda and Zimbabwe. | 518 participants; Eligible participants were HIV-negative, sexually active, had normal urinalysis, and no laboratory evidence of hepatic, renal, or hematological disease. | Cross-sectional |
+ (^a) |
Association between DMPA use and higher BMD at lumbar-spine and total hip | Medium |
| Levonorgestrel implant 150mg | Rocca, ML, et al.16 | 2021 | Systematic review | Not reported | To better understand how short- and long-term steroid contraceptives increase overall fracture risk. | Not applicable | Not applicable | Not significant (#) |
Similar or increased BMD | Not applicable |
| Implant (unspecified) | Golden, NH.21 | 2020 | Systematic review | Not reported | To summarize normal bone acquisition during adolescence, discusses methods of assessing bone health in this age group, and review the effects of different contraceptive options on bone health, both in adults and in adolescents. | Not applicable | Not applicable |
+/∼ (#b) |
No association between implant use and BMD loss | Not applicable |
#Not evaluated for statistical significance against baseline.
^Not evaluated for statistical significance compared to another group.
aHistory of using implant was statistically significantly associated with higher BMD at P<.05.
bFive studies found that there was not an adverse effect of implants on BMD, and 1 study found statistically significantly higher BMD in adolescents at 12 months at P<.05 compared to self at baseline.
Erhardt-Ohren. Bone mineral density changes during use of progestin-only contraceptives. Am J Obstet Gynecol 2025.
For items that presented results from different time periods under study, we separated out the time periods under analysis using commas in the “Duration” column, for example “6 months, 1 year” and the results in the “Magnitude of effect” column similarly, i.e., “3.0, 2.0." We did not include drug interaction studies or studies conducted in post-partum or post-abortion populations in the tables, but the study results are included in the narrative synthesis for each contraceptive method.
Results
Study selection, study characteristics, and risk of bias of included studies
We reviewed 24,723 titles, 1,456 abstracts, 720 full papers, and pulled 27 items from references for the broader side effects search. We included 429 items in the overall rapid review, and in this manuscript, present a synthesis of results from 3 systematic reviews, 24 original research articles, and 5 abstracts investigating the relationship between progestin-only contraceptives and bone health. Of the 24 original research articles, we judged 8 to be high quality, 15 to be medium quality, and 1 of low quality. We included 4 quantitative descriptive, 18 quantitative non-randomized, and 2 quantitative randomized controlled studies in the synthesis. Three items included in our review did not report location, 13 were in high-income countries, and 16 were in low- and middle-income countries. All randomized controlled trials included in the analyses were appropriately registered in a clinical trials registry and none had been retracted at the time of submission.
Oral contraceptives
We identified 1 systematic review without geographical information16 and 1 original research article that explored bone health changes during unspecified progestin-only oral contraception use in the United States.20 The systematic review reported that oral contraceptive use decreased or had no effect on BMD;16 the other study found a statistically significantly lower hazard ratio for fracture among dienogest progestin-only oral contraceptive users compared to other contraceptive user groups.20 The research article was a quantitative non-randomized design and considered high quality. With only these 2 items exploring bone health changes associated with progestin-only oral contraceptives, there is not enough information to draw a conclusion.
No studies evaluated the effect of various user demographics on bone health, healthcare provider-perceived side effects, or side effect treatment. Items that explored bone health changes with oral contraceptive use that we included in our synthesis, excluding postpartum, postabortion, and drug-drug interaction studies, are summarized in Table 1.
Injectables
We found 3 systematic reviews,16,21,22 21 original research articles,20,23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42 and 2 conference abstracts,43,44 that investigated the association between progestin-only injectable use and bone health changes. There were 1 low quality,36 13 medium quality,23, 24, 25, 26, 27,29, 30, 31, 32, 33,35,37,40 and 7 high quality studies20,28,34,38,39,41,42 included in our search. One study was a quantitative randomized controlled trial,27 16 were quantitative non-randomized studies,20,23, 24, 25,28, 29, 30,32, 33, 34, 35, 36,39, 40, 41, 42 and 4 were quantitative descriptive studies.26,31,37,38 No studies evaluated healthcare provider-perceived effects of progestin-only injectable contraceptives on bone health. Items that explored bone health changes with injectable contraceptive use, excluding postpartum, postabortion, and drug-drug interaction studies, that we included in our synthesis are summarized in Table 2.
Side effect experienced
The preponderance of the studies found a statistically significant negative association between DMPA injectable use and bone health. Specifically, 15 of the comparisons from high and medium quality studies reported that the use of DMPA injectables (of varying modes/doses) led to detrimental effects on bone health.16,20,22,23,25,26,27,32, 33, 34,36,37,40,42 7 comparisons found no significant association and included several medium and 1 high quality study.24,27,29,31,38,41 Lastly, wo studies did not report on the significance of associations.21,44
Among the articles included in this review, researchers generally found that the reduction of BMD associated with DMPA was somewhat reversible, though the level of treatment for BMD loss during use was low. Four studies included in a systematic review of the use of unspecified dosage DMPA injectables found that the reduction of BMD was partially reversible after discontinuation and unclear associations between longer duration of treatment and full BMD recovery.22 A second systematic review confirmed, through the findings of 3 studies, that partial or complete recovery of BMD occurred after DMPA discontinuation.21
Two studies assessed risk of fracture associated with DMPA use. One study reported that prior DMPA use was not associated with fracture risk.20 Another study investigating the odds of fracture among DMPA-IM 150mg users and non-users only found a statistically significant difference among users who had 3-9 DMPA-IM prescriptions (OR 2.41), but not 1−2 (OR 0.97) or 10+ prescriptions (OR 1.45).41 Even when adjusted for past DMPA injectable use, statistically significant association of fracture risk was found only with 10+ DMPA-IM prescriptions (OR 1.55); but not 1-2 (OR 0.96) or ≥3−9 prescriptions (OR 1.14).
Eleven studies took place in high-income countries,20,23, 24, 25,27,30,33,35,38,41,42 3 (all systematic reviews) did not report location,16,21,22 and twelve were in low- and middle-income countries.26,28,29,31,32,34,36,37,39,40,43,44 The only difference between studies in high-income countries and low- and middle-income countries were that that latter studies included those that investigated DMPA use among individuals with human immunodeficiency virus (HIV) infection. There were no differences in patterns between low- and middle-income countries and high-income countries; due to varying types of measurement, we were also unable to determine differences in baseline BMD measures across country income groups.
User demographics
Studies in the sample assessed whether and to what extent age, body mass index/weight, duration of use, diet, and use of Tenofovir Disoproxil Fumarate for HIV treatment impacted BMD and/or fracture risk. Studies generally found that adolescent girls were more likely to experience BMD loss, while the evidence on weight/body mass index and length of exposure was mixed. There is some evidence that diet and/dietary supplements can moderate the impact of DMPA on BMD. Studies also found that people living with HIV using Tenofovir Disoproxil Fumarate and DMPA were more likely to experience BMD loss.
One systematic review concluded that most evidence demonstrated that DMPA use before peak bone mass is achieved is detrimental to bone health, at least in the short term; the same study summarized 5 cross-sectional studies that confirmed that DMPA use has a more detrimental effect on the bones of 12-18 year-olds than adults.22 Another systematic review confirmed that adolescent DMPA users experienced an association between DMPA use and decreased BMD.21 One study looked at only individuals with past or current prescriptions, and found a statistically significant association between DMPA use and fracture in individuals under 30 years for those currently using DMPA (OR 3.04) and past use and fracture in individuals aged 30−33 years (OR 1.72).41
A study in the United Kingdom reported that there was not a statistically significant difference in broadband ultrasound attenuation, of which a lower value is considered a predictor of fracture risk, based on time exposure to DMPA-IM 150mg.25 The study did find that broadband ultrasound attenuation was negatively associated with increased age and that individuals who engaged in bone-loading activity while using DMPA injectables had statistically significantly lower broadband ultrasound attenuation. However, age is associated with decreases in bone mineral density, so it is unclear whether this loss is specifically related to DMPA injectable use.45
A study among normal weight, class 1-2 obese, and class 3 obese individuals did not identify statistically significant differences in BMD loss at the lumbar-spine after 18 weeks.23 Another study reported that there was increased fracture risk for individuals using DMPA with body mass index greater than 25 kg/m2 compared to other DMPA users with lower body mass index.41
A cross-sectional study in Uganda found that low consumption of bread, cereal, and milk was associated with lower lumber spine BMD in DMPA injectable users and not non-hormonal contraceptive users.44 Another study found that although vitamin B12 levels were lower in DMPA-IM 150mg users than in non-hormonal contraceptive users, there was not a statistically significant association between circulating B12 and BMD after adjusting for covariates.35 A 1-year prospective study reported that calcium intake attenuated BMD loss among DMPA-IM 150mg users.36
Three studies by the same researchers explored concurrent use of various antiretroviral therapy regimens and DMPA-IM 150mg. Two of these studies found that concurrent use of Tenofovir Disoproxil Fumarate and DMPA-IM 150mg was associated with statistically significant declines in total BMD, lumbar-spine BMD, and femoral neck BMD over time.39,43 A third study with HIV-positive and negative participants found that lumbar-spine BMD, total hip BMD, and femoral neck BMD were significantly lower for current HIV-positive DMPA-IM 150mg users compared to HIV-negative non-hormonal contraceptive users, HIV-positive non-hormonal contraceptive users, and HIV-positive previous DMPA-IM 150mg users.28
Side effect treatment
This side effect appears to be treated through method discontinuation, with evidence cited above pointing to the partial, or potentially full, recovery of BMD loss following discontinuation. One large retrospective study of DMPA-IM 150mg and DMPA-SC 104mg users in the United States found that 70% of users had a BMD test during DMPA use and very small minorities received treatment during DMPA use (1.65% used an estrogen supplement; 0.08% used bisphosphonate).20 The study did not report outcomes among treatment users.
Hormonal IUDs
We identified 2 systematic reviews,16,21 3 original research articles,20,46,47 and 2 conference abstracts48,49 that investigated the relationship between progestin-only hormonal IUD use and bone health. One original research article47 and conference abstract reported on the same findings.49 Of the original research articles, one was considered medium quality47 and 2 high quality.20,46 We evaluated 2 quantitative non-randomized studies20,47 and 1 quantitative randomized controlled trial.46 Four studies were conducted in high-income countries20,46,47,49 and 3 did not report location.16,21,48 No studies evaluated the effect of user demographics on the side effect, the beliefs of healthcare providers about the side effect, or side effect treatment. Items that explored bone health changes with hormonal IUD use, excluding postpartum, postabortion, and drug-drug interaction studies, that we included in our synthesis are summarized in Table 3.
Side effect experienced
Among the hormonal IUD studies, only 1, a conference abstract, reported a statistically significant negative association between hormonal IUD use and BMD z-scores at the lower hip.48 Four comparisons, including all 3 high quality and 1 medium quality studies, found no significant associations20,46,47,49 and 1 study did not report on significance.21 Only 1 systematic review reported a statistically significant increase in BMD among hormonal IUD users compared to other individuals in 3 out of 4 included studies.16
Implants
Two systematic reviews,16,21 2 original research articles,37,50 and 1 abstract51 investigated the relationship between the use of progestin-only implants and changes in bone health. Both original research articles were medium quality, 1 was quantitative descriptive37 and the other was quantitative non-randomized.50 Three studies did not report location16,21,51 and 2 studies were conducted in low- and middle-income countries.37,50 No studies assessed healthcare-provider perceived bone health effects or side effect treatment. Items that explored bone health changes with implant use that we included in our synthesis, excluding postpartum, postabortion, and drug-drug interaction studies, are summarized in Table 4.
Side effect experienced
Three comparisons found no significant differences in bone health measurements between implant users and others.16,50 Two other items (1 medium quality study and 1 conference abstract) found a positive association between implant use and bone health compared to other contraceptive users or selves at baseline.21,37
User demographics
One study assessed the effect of the etonogestrel implant 68mg on bone metabolism in lactating women aged 28–48 years old.51 This study reported that lactating individuals had similar bone metabolism to users of undefined “natural contraceptive methods” at 6 months after implant insertion.
Comment
Principal findings and comparison with existing literature
This is the first review to summarize evidence on bone health during and after use for 4 progestin-only contraceptive methods, which allows comparison across active pharmaceutical ingredients and routes of delivery. After reviewing 32 research items, we found that a preponderance of publications explored DMPA injectables and identified a link between use and BMD loss, especially among adolescents and individuals on Tenofovir Disoproxil Fumarate-containing antiretroviral regimens. A smaller body of evidence supports the partial or full restoration of BMD following DMPA injectable discontinuation. Fewer studies explored associations between other progestin-only contraceptive methods and bone health, but those that did appeared to show a positive relationship between implant or hormonal IUD use and bone health. There is not enough evidence on oral contraceptives to infer anything about the interaction between this method and bone health. Thus, the most significant gaps in the literature on progestin-only contraceptives and BMD loss are related to oral contraception use. More studies on implants and hormonal IUDs could provide definitive evidence to confirm the lack of negative impact on BMD loss. Such evidence is crucial but will require follow-up studies on users that include bone density measurements at the beginning of use (at baseline) and over time (every 2 years, as recommended by the National Osteoporosis Foundation52); reports of bone fractures during use; osteoporosis; and reports of other risk factors linked to BMD loss.
There is reason to be concerned about bone health during the use of progestin-only DMPA injectables given observed decreases in BMD, however, the clinical significance is less clear. Very few studies reported on the clinical significance of bone health changes, such as fracture risk16,20,22,41,42 and osteoporosis.40 Longer-term, 7 studies included in systematic reviews pointed to the partial or complete recovery of BMD following method discontinuation.21,22 Treatments for DMPA-related BMD loss are even less well studied. We only identified 1 study that looked at treatment for low BMD during contraceptive method use,30 and his single study reported on the number of individuals treated for contraceptive-related bone loss, but did not report on the outcomes of treatment. Overall, the effect of estrogen suppression on BMD during progestin-only contraceptive method use seems to be clear, but the degree of bone loss is also affected by factors such as age, diet, and exercise. Future studies should longitudinally assess the impact of progestin-only contraceptive methods on bone loss during use, following discontinuation, and the impact of various treatments on bone loss. However, these studies would not be without obstacles. These studies should utilize standardized measurements and employ prospective study designs to help account for potential confounding factors. The results of these studies, if they show that bone impacts are not clinically meaningful, may definitively settle questions about whether a Black Box warning for DMPA injectables is necessary.53,54,55 For other progestin-only contraceptive methods, the results of these studies may improve our confidence that only DMPA injectables have this impact and provide evidence that cost-intensive bone health testing does not need to be implemented during clinical trials for these other methods with well-known active pharmaceutical ingredients.
Strengths and limitations
While this is an important contribution to the scientific literature on the topic of bone health changes during progestin-only contraceptive use, this rapid review is subject to several limitations. Due to the abundance of literature on the topic of contraceptive side effects and our desire to synthesize and disseminate evidence in a timely fashion, we decided to conduct a rapid review instead of a systematic review. However, we searched 4 databases and reviewed all of the references of included studies for additional items. Our search also only included articles published in English from 2012 to 2023. This means we did not capture results in other language. We also specifically looked at literature from the past ten years relative to the time of the search: this means that we did not capture, in all cases, literature leading up to the launch of new products that are still in use, many of which were approved by the FDA and other global regulatory agencies before 2012. This is because we were interested in capturing the most recent evidence on the topic of BMD and progestin-only contraceptive use.
Conclusions and implications
In conclusion, there is clear evidence on the association between DMPA injectable use and decreased BMD, but there is a lack of research on potential treatments during contraceptive use, bone health restoration after method discontinuation, and the clinical relevance of any bone health changes. Progestin-only hormonal IUDs and implants seem to have the opposite effect of DMPA injectables, with a positive association with bone health. Oral contraception is under-researched and does not present a clear association. In our rapid review, we identify opportunities to increase the knowledge base of the effect of progestin-only contraceptives on bone health to support policy-makers, healthcare providers, and potential contraceptive method users make informed decisions.
CRediT authorship contribution statement
Blake Erhardt-Ohren: Writing – original draft, Methodology, Investigation, Conceptualization. Ndola Prata: Writing – review & editing, Validation, Methodology, Conceptualization. Scott Rosenblum: Supervision, Project administration, Methodology, Conceptualization.
Footnotes
PROSPERO registration #: CRD42022337263.
Registration date: June 13. 2022
Registration URL: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=337263
This rapid review was funded by the Gates Foundation. The Foundation provided input into the study design and decision to submit a manuscript. However, the authors’ views expressed in this publication do not necessarily reflect the views of the Gates Foundation. The authors report no conflict of interest.
Tweetable statement: Progestin-only contraceptives impact bone health differently: injectables, like DMPA, lower bone mineral density (BMD), while hormonal IUDs and implants do not. Recovery after DMPA discontinuation is possible.
Appendix A. Full set of search terms
-
•
Contraceptive methods keywords: (progestin-only OR progesterone-only OR “medroxyprogesterone 17-acetate” OR “medroxyprogesterone acetate” OR “17-medroxyprogesterone acetate” OR “depot medroxyprogesterone acetate” OR “depo provera” OR “depot provera” OR dmpa OR norethindrone OR net-en OR net-ent OR net-oen OR nuristerate OR “norethisterone oenanthate” OR “norethisterone enanthate” OR NETE OR “Sayana Press” OR DMPA-SC OR DMPA-IM OR medroxyprogesterone OR levonorgestrel OR LNG OR etonogestrel OR ENG OR “nestorone” OR “segesterone acetate” OR Jadelle OR Norplant OR Implanon OR Nexplanon OR Mirena OR Skyla OR Jaydess OR Kyleena OR Liletta OR progestagen OR desogestrel)
-
•
Side effect and adverse outcome keywords: (“side effects” OR ”sequelae” OR “sequela” OR “bone mineral density” OR “bone loss” OR “body composition” OR BMI OR “body mass index” OR “body weight” OR adipos* OR “binge eating” OR appetite OR bleeding OR menstruation OR “menstrual changes” OR hemorrhage OR “unscheduled bleeding” OR fertility OR ovulation OR fecundability OR fecundity OR “time to pregnancy” OR “ectopic pregnancy” OR “tubal pregnancy” OR (pregnancy AND extrauterine) OR “ectopic pregnancies” OR ”tubal pregnancies” OR (pregnancies AND extrauterine))
References
- 1.O. of the Commissioner . FDA; 2024. FDA Approves First Nonprescription Daily Oral Contraceptive.https://www.fda.gov/news-events/press-announcements/fda-approves-first-nonprescription-daily-oral-contraceptive Accessed: Dec. 24[Online]. Available: [Google Scholar]
- 2.Shoupe D. The Progestin Revolution: progestins are arising as the dominant players in the tight interlink between contraceptives and bleeding control. Contracept. Reprod. Med. Jan. 2021;6(1):3. doi: 10.1186/s40834-020-00142-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Edwards M., Can A.S. StatPearls. StatPearls Publishing; Treasure Island (FL): 2023. Progestin.http://www.ncbi.nlm.nih.gov/books/NBK563211/ Accessed: Dec. 27, 2023. [Online]. Available: [Google Scholar]
- 4.“Highlights of prescribing information: Depo-Provera CI.” Oct. 2010. Accessed: Dec. 09, 2022. [Online]. Available:https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020246s036lbl.pdf
- 5.“Highlights of prescribing information: Implanon.” Jul. 2014. Accessed: Dec. 09, 2022. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021529s008lblrev.pdf
- 6.“Highlights of prescribing information: Jadelle.” Dec. 2016. Accessed: Dec. 09, 2022. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020544s010lbl.pdf
- 7.“Highlights of prescribing information: Kyleena.” Sep. 2016. Accessed: Dec. 09, 2022. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208224s000lbl.pdf
- 8.“Highlights of prescribing information: Liletta.” Oct. 2019. Accessed: Dec. 09, 2022. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206229s008lbl.pdf
- 9.“Highlights of prescribing information: Mirena.” Oct. 2015. Accessed: Dec. 09, 2022. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021225s031lbl.pdf
- 10.“Highlights of prescribing information: Nexplanon.” Oct. 2018. Accessed: Dec. 09, 2022. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021529s018lbl.pdf
- 11.“Highlights of prescribing information: Skyla.” Access Data FDA, 2017.
- 12.“Highlights of prescribing information: Slynd.” Access Data FDA, May 2019. Accessed: Dec. 09, 2022. [Online]. Available:https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211367s000lbl.pdf
- 13.“Physician information: Depo-Provera Contraceptive Injection,” Access Data FDA. Accessed: Dec. 09, 2022. [Online]. Available:https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20246scs019_Depo-provera_lbl.pdf
- 14.“Highlights of prescribing information: Depo-Provera CI,” Access Data FDA.
- 15.“SAYANA PRESS 104 mg/0.65 ml suspension for injection - Summary of Product Characteristics (SmPC) - (emc).” Accessed: 2022. [Online]. Available:https://www.medicines.org.uk/emc/product/3148/smpc#gref
- 16.Rocca M.L., Palumbo A.R., Bitonti G., Brisinda C., Di Carlo C. Bone health and hormonal contraception. Minerva Obstet. Gynecol. 2021;73(6) doi: 10.23736/S2724-606X.20.04688-2. [DOI] [PubMed] [Google Scholar]
- 17.Hadji P., Colli E., Regidor P.-A. Bone health in estrogen-free contraception. Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA. 2019;30(12):2391–2400. doi: 10.1007/s00198-019-05103-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Characterizing progestin-only contraceptive side effects: a rapid review and narrative synthesis. PROSPERO. 2022 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=337263 Accessed: Dec. 09[Online]. Available: [Google Scholar]
- 19.Hong Q.N., Pluye P., Fàbregues S., Bartlett G., Boardman F., Cargo M. McGill University; 2018. Mixed methods appraisal tool (MMAT) 2018 criteria manual.http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/fetch/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf Accessed: Dec. 21, 2022. [Online]. Available: [Google Scholar]
- 20.Raine-Bennett T., Chandra M., Armstrong M.A., Alexeeff S., Lo J.C. Depot Medroxyprogesterone Acetate, Oral Contraceptive, Intrauterine Device Use, and Fracture Risk. Obstet. Gynecol. 2019;134(3):581–589. doi: 10.1097/AOG.0000000000003414. [DOI] [PubMed] [Google Scholar]
- 21.Golden N.H. Bones and Birth Control in Adolescent Girls. J. Pediatr. Adolesc. Gynecol. 2020;33(3):249–254. doi: 10.1016/j.jpag.2020.01.003. [DOI] [PubMed] [Google Scholar]
- 22.Nappi C., Bifulco G., Tommaselli G.A., Gargano V., Di Carlo C. Hormonal contraception and bone metabolism: a systematic review. Contraception. 2012;86(6):606–621. doi: 10.1016/j.contraception.2012.04.009. [DOI] [PubMed] [Google Scholar]
- 23.Segall-Gutierrez P., Agarwal R., Ge M., Lopez C., Hernandez G., Stanczyk F.Z. A pilot study examining short-term changes in bone mineral density among class 3 obese users of depot-medroxyprogesterone acetate. Eur. J. Contracept. Reprod. Health Care. 2013;18(3):199–205. doi: 10.3109/13625187.2013.774358. [DOI] [PubMed] [Google Scholar]
- 24.Roden R.C., Noritz G., McKnight E.R., Bonny A.E. An exploratory study of depot-medroxyprogesterone acetate and bone mineral density in adolescent and young adult women with cerebral palsy. Contraception. 2020;101(4):273–275. doi: 10.1016/j.contraception.2019.12.009. [DOI] [PubMed] [Google Scholar]
- 25.Babatunde O.O., Forsyth J.J. Association between depot medroxyprogesterone acetate (DMPA), physical activity and bone health. J. Bone Miner. Metab. 2014;32(3):305–311. doi: 10.1007/s00774-013-0497-y. [DOI] [PubMed] [Google Scholar]
- 26.Mahran D.G., Hussein M., Farouk O. Bone mineral density among reproductive age women in rural Upper Egypt. J. Public Health. 2012;20(4):453–460. doi: 10.1007/s10389-011-0469-4. [DOI] [Google Scholar]
- 27.Lange H.L.H., Manos B.E., Gothard M.D., Rogers L.K., Bonny A.E. Bone Mineral Density and Weight Changes in Adolescents Randomized to 3 Doses of Depot Medroxyprogesterone Acetate. J. Pediatr. Adolesc. Gynecol. 2017;30(2):169–175. doi: 10.1016/j.jpag.2016.10.011. [DOI] [PubMed] [Google Scholar]
- 28.Matovu F.K., et al. Bone Mineral Density in Antiretroviral Therapy-Naïve HIV-1–Infected Young Adult -Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda. JBMR Plus. 2021;5(2) doi: 10.1002/jbm4.10446. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Beksinska M.E., Kleinschmidt I., Smit J.A. Bone mineral density in midlife long-term users of hormonal contraception in South Africa: relationship with obesity and menopausal status. Womens Midlife Health. 2018;4(1):6. doi: 10.1186/s40695-018-0035-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Eworuke E., Popat V., Moeny D.G. Bone mineral density testing, and bisphosphonate and oestrogen prescribing associated with depot medroxyprogesterone acetate utilization-The impact of the boxed warning. J. Clin. Pharm. Ther. 2017;42(4):483–494. doi: 10.1111/jcpt.12561. [DOI] [PubMed] [Google Scholar]
- 31.Begum R.A., Ali L., Takahashi O., Fukui T., Rahman M. Bone mineral density: reference values and correlates for Bangladeshi women aged 16–65 years. J. Orthop. Sci. 2015;20(3):522–528. doi: 10.1007/s00776-015-0695-7. [DOI] [PubMed] [Google Scholar]
- 32.Quintino-Moro A., Zantut-Wittmann D.E., Silva dos Santos P.N., Silva C.A., Bahamondes L., Fernandes A. Changes in calcium metabolism and bone mineral density in new users of medroxyprogesterone acetate during the first year of use. Int. J. Gynecol. Obstet. 2019;147(3):319–325. doi: 10.1002/ijgo.12958. [DOI] [PubMed] [Google Scholar]
- 33.Nieves J.W., et al. Eating disorders, menstrual dysfunction, weight change and DMPA use predict bone density change in college-aged women. Bone. 2016;84:113–119. doi: 10.1016/j.bone.2015.12.054. [DOI] [PubMed] [Google Scholar]
- 34.M. Zhang, Z. Wei, Z. Ai-dong, Y. Yan, and G. Ling, “Effect of depot medroxyprogesterone acetate on bone mineral density in adolescent women,” Chin. Med. J. (Engl.), vol. 126, no. 21, p. 5. [PubMed]
- 35.Berenson A.B., Rahman M. Effect of hormonal contraceptives on vitamin B12 level and the association of the latter with bone mineral density. Contraception. 2012;86(5):481–487. doi: 10.1016/j.contraception.2012.02.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Modesto W., Bahamondes M.V., Silva dos Santos P., Fernandes A., Dal’Ava N., Bahamondes L. Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate. Eur. J. Contracept. Reprod. Health Care. 2014;19(4):244–249. doi: 10.3109/13625187.2014.924098. [DOI] [PubMed] [Google Scholar]
- 37.Mgodi N.M., et al. Factors associated with bone mineral density in healthy African women. Arch. Osteoporos. 2015;10(1):3. doi: 10.1007/s11657-015-0206-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Coombs C.V., O’Leary T.J., Tang J.C.Y., Fraser W.D., Greeves J.P. Hormonal contraceptive use, bone density and biochemical markers of bone metabolism in British Army recruits. BMJ Mil. Health. 2021 doi: 10.1136/bmjmilitary-2020-001745. p. bmjmilitary-2020-001745, Mar. [DOI] [PubMed] [Google Scholar]
- 39.Matovu F.K., et al. Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda. Lancet Glob. Health. 2022;10(5):e694–e704. doi: 10.1016/S2214-109X(22)00080-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Modesto W., Bahamondes M.V., Bahamondes L. Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate. J. Womens Health. 2015;24(8):636–640. doi: 10.1089/jwh.2014.5077. [DOI] [PubMed] [Google Scholar]
- 41.Kyvernitakis I., Kostev K., Nassour T., Thomasius F., Hadji P. The impact of depot medroxyprogesterone acetate on fracture risk: a case-control study from the UK. Osteoporos. Int. 2017;28(1):291–297. doi: 10.1007/s00198-016-3714-4. [DOI] [PubMed] [Google Scholar]
- 42.Lanza L.L., et al. Use of Depot Medroxyprogesterone Acetate Contraception and Incidence of Bone Fracture. Obstet. Gynecol. 2013;121(3):593–600. doi: 10.1097/AOG.0b013e318283d1a1. [DOI] [PubMed] [Google Scholar]
- 43.Matovu F., Babirye J., Nabwana M. Depo-Provera worsens bone loss with TDF-containing ART initiation in young women. Journal of the International AIDS Society. 2020 doi: 10.1002/jia2.25547. [DOI] [Google Scholar]
- 44.Matovu N., Matovu F. Dietary patterns and bone mineral denisty among long term users of depot medroxyprogesterone acetate compared to non hormonal contraceptive users, Kampala Uganda. Ann. Nutr. Metab. 2017;71(2) [Google Scholar]
- 45.Demontiero O., Vidal C., Duque G. Aging and bone loss: new insights for the clinician. Ther. Adv. Musculoskelet. Dis. 2012;4(2):61–76. doi: 10.1177/1759720X11430858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Nelson A., et al. Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: A Randomized Controlled Trial. Obstet. Gynecol. 2013;122(6):1205–1213. doi: 10.1097/AOG.0000000000000019. [DOI] [PubMed] [Google Scholar]
- 47.Yang K.Y., Kim Y.S., Ji Y.I., Jung M.H. Changes in Bone Mineral Density of Users of the Levonorgestrel-releasing Intrauterine System. J. Nippon Med. Sch. 2012;79(3):190–194. doi: 10.1272/jnms.79.190. [DOI] [PubMed] [Google Scholar]
- 48.Miller D.L., Gray A., Manning P. A cross-sectional study of hip and spine bone mineral density in users of the levonorgestrel-releasing intrauterine system. Fertil. Steril. 2013;100(3):S313–S314. doi: 10.1016/j.fertnstert.2013.07.964. [DOI] [Google Scholar]
- 49.World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2019): Posters Abstracts. Osteoporos Int 30 (Suppl 2), 253–773 (2019). 10.1007/s00198-019-04993-w [DOI] [PubMed]
- 50.Modesto W., Dal´Ava N., Monteiro I., Bahamondes L. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. Arch. Gynecol. Obstet. 2015;292(6):1387–1391. doi: 10.1007/s00404-015-3784-0. [DOI] [PubMed] [Google Scholar]
- 51.Iltemir Duvan C., Onaran Y., Aktepe Keskin E., Yanik B., Kafali H., Ozturk Turhan N. Does etonogestrel contraceptive implant (Implanon) effect bone metabolism during lactation period? Fertil. Steril. 2013;100(3):S314. doi: 10.1016/j.fertnstert.2013.07.965. [DOI] [Google Scholar]
- 52.National Osteoporosis Foundation; Washington, DC: 2013. Bone Density Testing.https://www.bonehealthandosteoporosis.org/wp-content/uploads/2016/02/Bone-Density-Testing.pdf Accessed: Aug. 26, 2024. [Online]. Available: [Google Scholar]
- 53.“Remove the black-box warning for depot medroxyprogesterone acetate!” Accessed: Sep. 02, 2024. [Online]. Available:https://www.mdedge.com/obgyn/article/64428/gynecology/remove-black-box-warning-depot-medroxyprogesterone-acetate
- 54.Kaunitz A.M., Grimes D.A. Removing the black box warning for depot medroxyprogesterone acetate. Contraception. 2011;84(3):212–213. doi: 10.1016/j.contraception.2011.01.009. [DOI] [PubMed] [Google Scholar]
- 55.Cromer B.A., et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents–the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J. Adolesc. Health Off. Publ. Soc. Adolesc. Med. 2006;39(2):296–301. doi: 10.1016/j.jadohealth.2006.03.011. [DOI] [PubMed] [Google Scholar]
